Skip to main content
. Author manuscript; available in PMC: 2014 Apr 30.
Published in final edited form as: Cancer Res. 2013 Oct 4;73(20):6149–6163. doi: 10.1158/0008-5472.CAN-12-4617

Table 2.

Sunitinib and dasatinib inhibit brain metastases in preclinical models

231-Br-HER2+ model 231-Br-HER2− model


Treatment N Large
metastases
mean (95% CI)
P Micro
metastases
mean (95% CI)
P N Large
metastases
mean (95% CI)
P Micro
metastases
mean (95% CI)
P
Vehicle 18 20 (18–23) ref 293.6 (255.1–332.1) ref 19 15 (12–17) ref 218.3 (185.3–251.3) ref
Sunitinib 80 mg/kg 17 14 (12–15) 0.02 199.8 (175.7–223.9) 0.05 16 10 (9–11) 0.03 150.2 (128.2–177.2) 0.06
Sunitinib 40 mg/kg 16 16 (14–18) 0.05 228.1 (199.8–256.4) 0.07 17 12 (10–14) 0.08 156.1 (131.1–181.1) 0.05
Dasatinib 50 mg/kg 14 9 (7–10) 0.02 113.2 (89.4–137) 0.01 16 8 (6–8) 0.02 99.5 (89.2–109.8) 0.009
Dasatinib 25 mg/kg 15 13 (11–14) 0.04 175.7 (147.9–203.5) 0.04 18 9 (7–10) 0.03 144.6 (132.1–157.1) 0.012

NOTE: Mice were injected with 1.75 × 105 231-Br-HER2+ or 231-Br-HER2− cells through the left ventricle and treated with sunitinib, dasatinib, or vehicle starting three days later. The treatment was carried out once daily for 28 days. Numbers of metastases were determined in 10-step sections from each mouse brain described in Materials and Methods. CI, confidence interval. For each group of data, the normality was examined with the Jarque–Bera test first, and then Levene F test was used to test multigroup HOV. If the groups enrolled followed the HOV, the Student t test was used for analyzing experimental data; if not, the Wilcoxon rank test was executed. All P values are two-sided.